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INTRODUCTION
Impairment in left ventricular geometry and function
represents a strong predictor for cardiovascular mortal-
ity and the occurrence of myocardial infarction, heart
failure and stroke in hypertensive patients and general
population (1, 2) Accordingly, reduction in left ventricu-
lar mass and regression of left ventricular hypertrophy
(LVH) is today one of the most important goals of anti-
hypertensive therapy (3, 4). Disproportional accumula-
tion of fibrous tissue is a major characteristic of the ad-
verse structural remodelling of cardiac tissue in hyper-
tensive subjects. An increase in fibrillar collagen depo-
sition determines a rise of interstitial and perivascular fi-
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ABSTRACT: Background. In this study the effects of 24 weeks losartan and ramipril treatment,
both alone and in combination, on blood pressure and left ventricular mass (LVM) and function,
have been evaluated in hypertensives. 
Methods. 57 hypertensives with stage 1 and 2 essential hypertension were included. After 4
weeks run in, a randomized double-blind, 3 arm, double dummy, independent trial was used. All
patients were randomly allocated to 3 treatment arms consisting of losartan (50 mg/daily),
ramipril (5 mg/daily), and combined (losartan 50 mg/ramipril 5 mg/daily) for 24 weeks. LVM,
LVM/h
2.7 and other echocardiographic measurements, BUN, creatinine and clearance and potas-
sium were determined after run in and 24 weeks. 
Results. All groups were comparable for gender, age, BMI, BP and LVM. The prevalence of
baseline left ventricular hypertrophy (LVH) was not significantly different among 3 groups. At the
end of treatment, a significant (p<0.05) reduction in SBP, DBP, MBP, LVM and LVM/h
2.7 were ob-
served in all groups. The absolute and percent reduction in LVM/h
2.7 were significantly higher in
combined than losartan or ramipril groups and also in hypertensives with LVH. No significant
change in absolute and percent reduction of SBP, DBP and MBP were found. 
Conclusions. These data indicate an additional cardioprotective effect of dual blockade of RAS
in hypertensive patients with and without left ventricular hypertrophy. (Heart International 2006;
2: 39-48)
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brosis in cardiac ventricles (5). The increased collagen
and unchanged or insufficient degradation by collage-
nase (6) has been reported to promote systolic dysfunc-
tion, myocardial stiffness and abnormalities in diastolic
ventricular filling and relaxation (7). Hemodynamic and
non hemodynamic factors play a main role in the colla-
gen turnover in hypertension (8, 9). Experimental data
suggest that Angiotensin II stimulates fibroblast-medi-
ated collagen synthesis (10, 11) independently of me-
chanical load either directly or via specific growth fac-
tors (12) and inhibits collagenase. 
Even if antihypertensive drugs reverse left ventricu-
lar hypertrophy (LVH) by lowering blood pressure (13),
meta-analyses of clinical trials have demonstrated that
ACE-inhibitors (ACEi) and A-II type 1 receptor blockers
(ARB) decrease left ventricular mass most effectively
than  other  antihypertensive  drugs  (14).  Moreover,
some recent studies have reported that the combina-
tion of two agents, ACEi and ARB, that inhibit two con-
secutive renin-angiotensin-system (RAS) steps, pro-
motes a decrease in myocardial fibrosis and left ven-
tricular hypertrophy (15-18). This effect is due to a di-
minished AT1 receptor activation by a decreased An-
giotensin II production. Other data indicate that ad-
ministration of ACEi may be able to reduce the colla-
gen content with consequent improvement of diastolic
filling (16). Clinical data, comparing ACEi and ARB
therapy in hypertensive heart disease, indicate that
ARB have equivalent effects to ACEi on blood pressure
and left ventricular hypertrophy (19), and these actions
seem partially independent of their hemodynamic ef-
fects (8). In addition, experimental and clinical studies
indicate that the combination of low doses of ACEi and
ARB have a synergic and most effectiveness on left
ventricular hypertrophy (20, 21). These effects might
explain a better cardioprotection attributed to ACEi
and ARB than other antihypertensive drugs. Although
a  combination  of  ACEi  and  ARB  treatment  seems 
actractive, thus far limited data have emerged to sup-
port such as strategy. 
Accordingly, the main goal of the present study was
to determine the effects of 24 weeks’ losartan and
ramipril administration on measurements of left ven-
tricular geometry and function in hypertensive pa-
tients. For this reason hypertensive subjects were allo-
cated randomly to 24 weeks of treatment with ACEi
and ARB alone or in combination.
SUBJECTS AND METHODS
Patients 
Subjects eligible for the study were screened for ar-
terial hypertension at the antihypertensive center of the
Department of Internal Medicine, University of Palermo,
Italy. Subjects with a casual systolic blood pressure
(SBP) ￿ 140 mmHg and < 180 mmHg and/or with casual
diastolic blood pressure (DBP) ￿ 90 mmHg and < 110
mmHg obtained with a standard sphygmomanometer
after 5 min of rest on three independent occasions,
were invited to our day hospital for a detailed medical
examination including history taking, physical, routine
laboratory and echocardiographic examination. Exclu-
sion criteria included the presence of any form of sec-
ondary hypertension; stage III essential hypertension,
any irreversible end organ damage due to arterial hy-
pertension; metabolic bone disease, hyperthyroidism,
cardiovascular disease, diabetes, dyslipidemia, hepatic
disease, alcoholic liver disease, malignants. According-
ly, from a large number of hypertensives, we established
three groups of patients single matched for age, gender,
body mass index (BMI) , SBP and DBP. Fifty-seven pa-
tients fullfilled the selection criteria and baseline char-
acteristics of the study participants are given in Table I. 
Study design and active treatment 
Each patient gave a written consent after having re-
ceived a detailed description of the study procedure.
The study was approved by the Ethics Committee of our
Institution. Multiple comparisons power analysis was
performed to determine sample size. The primary end-
point was considered the level of TGF-β1 changes and
sample size was computed basing on the following as-
sumptions: α = 0.05, power of at least 0.80 (β error
equal or below 0.20), a minimum detectable difference
of 3.00 with a standard deviation of 2.00 (minimum de-
tectable difference/standard deviation =1.5). The total
sample size resulted in 57 subjects (19 subjects for
each of the three arms); it achieved 83% power using
the Hsu (With Best) multiple comparison test at 0.05000
significance level.
This study was a randomized, double-blind, three-
arm double-dummy independent trial. It was planned
and conducted according to the revised recommenda-Argano et al
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tions for improving the quality of report or randomised
trial (22). We studied three groups of subjects each of
them matched for age, BMI, and blood pressure values.
Then, groups were randomly allocated into one of the
three therapy arms. The first arm was treated with losar-
tan 50 mg/day, the second arm was treated with ramipril
5 mg/day, and the third was treated with a combination
of the two drugs (losartan 50 mg plus ramipril 5 mg).
(Fig. 1). Blood pressure normalization (SBP ￿140 mmHg
and DBP ￿90 mmHg) occured in all hypertensives. To
achieve this goal only a few patients in each treatment
group also received hydrochlorotiazyde (12.5 mg once
daily) (losartan group n= 1 patient; ramipril group n= 1
patient; combined group n= 1 patient). The follow-up
was 24 weeks.
Each patient entered into the study was uniquely
identified for study purposes by a four-digit patient
number, and each group was labelled by a letter corre-
sponding to drug regimen that was concealed until sta-
tistical analysis was complete. The drug regimen was
TABLE I - EFFECTS OF TREATMENTS ON BLOOD PRESSURE AND CLINICAL MEASUREMENTS 
Losartan Ramipril Combined
Cases 19 19 19
Baseline Treatment Baseline Treatment Baseline Treatment
Sex (F/M) 10/9 10/9 10/9 10/9 10/9 10/9
Age (years) 56 ± 7 56 ± 7 54 ± 8 54 ± 8 57 ± 7 57 ± 7
BMI (kg/m
2) 31.6 ± 4.9 31.2 ± 4.8 29.7 ± 4.3 29.3 ± 4.1 30 ± 5 29.5 ± 4.5
SBP (mmHg) 162 ± 70 133± 5* 159 ± 70 134 ± 5*. 161 ± 80 131 ± 6*.
DBP (mmHg) 94 ± 6 .82 ± 7* 98 ± 9 .81 ± 8* 094 ± 12 .78 ± 8*
MBP(mmHg) 116 ± 80 100 ± 6*. 118 ± 90 100 ± 8*. 116 ± 90 095 ± 7*
BUN (mg/dL) 42 ± 9 42 ± 8 37 ± 9 38 ± 6 42 ± 7 43 ± 6
Creatinine (mg/dL) 1.01 ± 0.2 1.03 ± 0.2 0.99 ± 0.1 0.99 ± 0.2 1.02 ± 0.2 1.03 ± 0.2
Creatinine clearance (mL/min) 089 ± 14 ..87 ± 17 93 ± 9 094 ± 15 090 ± 13 089 ± 15
Potassium (mEq/L) 04.5 ± 0.3 04.6 ± 0.6 04.6 ± 0.4 04.8 ± 0.5 04.6 ± 0.2 04.9 ± 0.6
BMI: Body Mass Index. SBP: Systolic blood pressure. DBP: Diastolic blood pressure. MBP: Mean blood pressure. BUN: Blood Urea Ni-
trogen. 
*p< 0.05 vs baseline
Fig. 1 - Trial profile.RAS blockade and cardioprotection
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double-dummy, so each group received two tablets
(one pharmacologically active plus placebo, except the
group  that  received  two  pharmacologically  active
drugs). Both placebo and active drug tablets were in-
distinguishable but for a letter label. Severe adverse re-
actions  were  monitored  to  enable  the  study  to  be
stopped early if they emerged. The patient code was re-
vealed to the clinical researchers once recruitment, da-
ta collection, laboratory analyses and statistical analy-
sis were completed. No patient dropped out of the
study, so all data of all patients were collected and
analysed. An independent biostatistics expert analysed
data and performed inferential analysis. All data analy-
sis was carried out according to a pre-established
analysis plan.
The patients attended the clinic for a total of eight
study visits: at 4 and 2 weeks before randomization, at
randomization (week 0), and at 1, 6, 12, 18 and 24
weeks after randomization. At each visit blood pressure
was measured in the morning after 5 min of rest, about
24 hours after the previous drug administration. Sitting
blood pressure was measured three times with an inter-
val of about 2 min, and the mean was calculated. Mean
blood pressure (MBP) was calculated by the formula
DBP plus 1/3 of pulse pressure. At 0 and 24 weeks after
randomization, both biochemical and echocardiograph-
ic measurements, circulating TGFβ1, PIP and PIIIP were
determined. 
Measurements
Patients underwent a general analytical laboratory
parameters profile including BUN, creatinine and clear-
ance, glycemia, electrolytes (serum sodium, potassium,
chloride), by routine laboratory methods.
Echocardiographic measurements
All patients underwent an echocardiography exami-
nation M and B-mode, by a computerized echocardiog-
raphy (ESAOTE, Italy) for the determination of following
parameters: left ventricular telediastolic internal diame-
ter (LVIDd), interventricular septum (IVSTd), and poste-
rior wall thickness (PWTd). The Penn convention was
used to calculate left ventricular mass (LVM). LVM was
normalized for height to the 2.7 power (23). According-
ly, all the hypertensives with LVM/h2.7 ￿ 50 g/m2.7 for men
and ￿ 47 g/m2.7 for women were considered to have left
ventricular hypertrophy (LVH). The prevalence of hyper-
tensives with LVH into three treatment groups was not sig-
nificantly different (Losartan group n. 10/19; Ramipril
group n.10/19; Combined treatment group n.11/19). The
relative wall thickness (RWT) by formula [(PWTd/LVIDd)x2]
was also calculated. Ejection fraction from left ventricular
end-diastolic and end-systolic volumes was measured
from the apical four chamber view, using the ellipsoidal
single-plane algorithm. Mean ejection fraction was auto-
matically calculated by the echocardiographic processing
system. In our laboratory the ejection fraction calculated
over five consecutive beats permitted optimal repro-
ducibility and accuracy (24). 
LV relaxation and filling were evaluated by pulsed-
wave Doppler interrogation of the LV inflow tract from
the apical four-chamber view, with the sample volume
placed at the tips of the mitral valve. After a stable sig-
nal of the transmitral flow velocity was obtained, the
Doppler cursor was moved toward the LV outflow tract
in the apical five-chamber view for recording both mitral
and aortic signals, including the closing click of the aor-
tic valve and the opening click of the mitral valve.
Doppler  signals  were  recorded  at  high  speed  (80-
120mm/s) with the subjects in held expiration. An aver-
age of five beats was used for analysis. 
Isovolumic relaxation time (IVRT) was calculated as
the time from the closure click of the aortic valve to the
opening click of the mitral valve. When either the clos-
ing or opening click was not identified, the time from the
end of the aortic flow to the onset of mitral flow from the
continuous wave interrogation of the LV inflow-outflow
tract was used. Peak early transmitral flow velocity (E),
peak late transmitral flow velocity (A), and the decelera-
tion time of E velocity (DTE) were measured at the tips of
mitral leaflets at the maximum amplitude of E velocity.
DTE was measured as the time from peak E velocity to
the time when E wave descent intercepts the zero line. 
Statistical analysis
Data are expressed as mean value ± standard devia-
tion. Non parametric tests were performed to test null
hypothesis and two-sided value of p < 0.05 indicated a
statistical significant difference. The Wilcoxon signed
ranks test was performed to compare data at baseline
and after treatment within groups. Groups’ data both atArgano et al
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baseline and after treatment changes were compared
by the Kruskall-Wallis test used as a non-parametric al-
ternative to the one way ANOVA. Pairwise comparisons
between groups were performed using the Conover-In-
man method when the Kruskall-Wallis indicated a sig-
nificance among groups.
RESULTS 
No significant differences in baseline age, BMI, SBP,
DBP,  MBP,  routine  biochemical  measurements  and
echocardiographic measurements were observed for the
losartan, ramipril and combination groups (Tabs. I, II). 
Significant (p<0.05) decrease in SBP, DBP, MBP, total
and indexed LVM values were observed in all the groups
at the end of treatment compared to baseline values. In
all groups no significant changes in biochemical mea-
surements and in the remaining echocardiographic pa-
rameters were found at the end of treatment (Tabs. I, II).
Figure 2 shows the responses of LVM/h2.7 values of in-
dividuals to the three treatments. 
In the combination therapy group a significant in-
crease in the absolute reduction of LVM/h2.7 (p< 0.05 vs
losartan; p< 0.001 vs ramipril) was found. The percent
reduction in LVM/h (p< 0.05 vs losartan; p< 0.03 vs
TABLE II - EFFECTS OF TREATMENTS ON ECHOCARDIOGRAPHIC PARAMETERS 
Losartan Ramipril Combined
Cases 19 19 19
Baseline Treatment Baseline Treatment Baseline Treatment
LVIDd (mm) 0.48 ± 3.9 45.5 ± 4.1 46.8 ± 4.1 45.6 ± 4.4 47.6 ± 3.6 43.2 ± 2.8
IVSTd (mm) 10.2 ±.1.3 .9.8 ±1.2 11.5 ± 1.1 11.2 ± 1.1 11.2 ± 1.6 0.11 ± 1.8
PWTd (mm) 09.8 ± 1.6 09.4 ±.1.6 10.5 ± 1.4 09.5 ± 1.5 10.4 ± 1.3 09.4 ±.1.3
RWT [(PWTd / LVIDd)x2] 00.41 ± 0.05 00.41 ± 0.06 00.45 ± 0.07 00.42 ± 0.08 00.44 ± 0.06 00.44 ± 0.08
LVM (g) 174 ± 46 .151 ± 42* 183 ± 31 0155 ± 34* 188 ± 41 .139 ± 29*
LVM/h
2.7 (g/m
2.7) 047 ± 14 0.41 ± 12* 049 ± 10 041 ± 9* 052 ± 16 0.39 ± 13*
LVEF (%) 65 ± 4 65 ± 4 62 ± 5 62 ± 3 63 ± 5 64 ± 4
E/A velocity ratio 1.12 ± 0.8 01.3 ± 0.6 0.98 ± 0.5 01.1 ± 0.4 1.02 ± 0.6 1.43 ± 0.3
DTE (ms) 212 ± 41 196 ± 33 225 ± 50 210 ± 32 222 ± 47 189 ± 21
IVRT (ms) 097 ± 23 089 ± 20 100 ± 23 089 ± 16 102 ± 23 087 ± 12
LVIDd: Left ventricular internal diastolic diameter. IVSTd: Interventricular septum thickness diastolic. PWTd: Posterior wall thickness.
RWT: relative wall thickness. LVEF: Left ventricular ejection fraction. LVM: left ventricular mass. LVM/h2.7: left ventricular mass normalized
to height 2.7. E/A: velocity ratio: peak early transmitral flow velocity (E), peak late transmitral flow velocity (A) ratio. DTE: E deceleration
time. IVRT: isovolumic relaxation time.
*p< 0.05 vs baseline
TABLE III - ABSOLUTE AND PERCENT REDUCTION (∆) LEFT VENTRICULAR MASS AND BLOOD PRESSURE IN THE THREE GROUPS
Losartan n 19 Ramipril n 19 Combined n 19
∆ LVM/h2.7 (g/m2.7) 6.4 ± 5 ..8.5 ± 8.5 0.14 ± 7‡§
∆ LVM/h2.7 (%) .14 ± 9 016 ± 16 00.24 ± 15‡§
∆ SBP (mmHg) .29 ± 9 025 ± 12 030 ± 11
∆ SBP (%) .18 ± 5 16 ± 7 19 ± 6
∆ DBP (mmHg) .14 ± 9 017 ± 11 017 ± 12
∆ DBP (%) 0.14 ± 11 018 ± 10 017 ± 12
∆ MBP (mmHg) .16 ± 8 18 ± 9 021 ± 11
∆ MBP (%) .14 ± 7 15 ± 7 18 ± 8
LVM/h2.7: left ventricular mass normalized to height2.7. SBP: Systolic blood pressure. DBP: Diastolic blood pressure. MBP: Mean blood
pressure. 
Kruskall-Wallis test:
‡ p < 0.05 vs Losartan § p < 0.03 vs RamiprilRAS blockade and cardioprotection
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ramipril) was also higher in the combination group. No
significant changes in absolute and percent changes in
SBP, DBP and MBP was detected between the three
groups (Tab. III).
Table IV shows the effects of treatment on LVM,
LVM/h2.7 and on percent reduction of LVM/h2.7 in a sub-
set of hypertensives with baseline LVH. 
LVM and LVM/h2.7 were significantly (p< 0.05) re-
duced at the end of treatment in all groups. Percent re-
duction in LVM/h2.7 was significantly higher in combined
group than ramipril (p< 0.02) and losartan (p< 0.01). Hy-
pertensives  with  normalized  LVM  was  similar  in  all
groups (losartan 6/10; ramipril 7/10; combined 7/11).
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Fig. 2 - Individual responses of LVM/h2.7 over the 24 weeks’ treat-
ment with losartan, ramipril and the combined treatment.
a RAMIPRIL LOSARTAN
COMBINED
b
c
TABLE IV - EFFECTS OF TREATMENTS ON TOTAL AND INDEXED LEFT VENTRICULAR MASS AND ON ITS PERCENT REDUCTION IN
HYPERTENSIVES WITH BASELINE LEFT VENTRICULAR HYPERTROPHY
Losartan Ramipril Combined
Cases 10 10 11
Baseline Treatment Baseline Treatment Baseline Treatment
LVM (gr) 203 ± 37 172 ± 31* 198 ± 30 157 ± 38* 213 ± 25 153 ± 27*
LVM/h2.7 (g/m2.7) 58 ± 8 49 ± 8* 57 ± 8 46 ± 9* 63 ± 10 46 ± 12*
∆ LVM/h2.7 (%)  16  19  27† ‡
LVM: left ventricular mass. LVM/h2.7: left ventricular mass normalized to height2.7
∆ LVM/h2.7: Percent reduction in left ventricular mass normalized to height2.7
Kruskall-Wallis test:
* p<0.05 vs baseline; †p<0.02 vs ramipril; ‡ p<0.01 vs losartanArgano et al
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All treatment regimens were generally well tolerated.
Side effects were few and transient. Two patients com-
plained of asthenia, two of cough and three of dizziness
but treatments were not discontinued.
DISCUSSION 
In the present study we hypothesized that complete
inhibition of the RAS would be most beneficial in man-
agement of left ventricular geometry and function in hy-
pertensive patients and might be achieved by a dual
blockade with ACEi and ARB. To prove this hypothesis
we compared the effects of three treatments (monother-
apy with ACEi and ARB and its combination) on blood
pressure, left ventricular mass and function in hyperten-
sive subjects. This was an independent single-center
trial which, compared with multicenter trials, may have
some benefits, such as a simple design, strict imple-
mentation and constant analysis of clinical and labora-
tory data. This is the first study designed to analyze the
effects of dual RAS blockade on left ventricular mass
and function in hypertensives. 
Our results indicate an interesting finding. In fact, a
more marked reduction in total and indexed left ventric-
ular mass without impairment in diastolic and systolic
left ventricular function following the combination of
ACEi and ARB than either drug alone has been found in
hypertensive subjects. In fact, the reduction in LVM/h2.7
after 6 months of combined therapy, was significantly
higher than LVM/h2.7 reduction obtained with both sin-
gle treatment, both in total hypertensives and in the
subset with baseline LVH. This reduction was associat-
ed to unchanged EF and to a favorable trend in the mea-
surements of diastolic function. It is important to em-
phasize that this effect was obtained with strict blood
pressure control in all the groups. This finding discounts
the suggestion that the differences observed upon the
reduction in LVM could be explained only by the sys-
temic blood pressure effect.
Cardioprotection induced by combined therapy ob-
served by us has been reported previously in experi-
mental studies and in patients with hypertensive dias-
tolic heart failure (25). The exact mechanism of this find-
ing is not entirely known but emerging data indicate a
strong  relationship  among  Angiotensin  II,  collagen
turnover and left ventricular geometry and function (26).
Accordingly, our hypothesis about a better cardiopro-
tective  effect  induced  by  combined  RAS  blockade
might  be  related  to  the  well  known  effects  of  An-
giotensin II both on blood pressure, systemic and car-
diac hemodynamics (27, 28) and on inflammatory mark-
ers (29). ACEi reduce Angiotensin II but do not com-
pletely block the RAS, since Angiotensin II may be pro-
duced via other non-ACE-mediated pathways. Block-
ade of AT1 by ARB may also reduce the unfavorable ef-
fects of Angiotensin II. This might also induce a higher
available Angiotensin II to bind with AT2 receptors; the
latter may lead to relevant antigrowth and antitissue
proliferation actions (27, 28). In particular, ARB also
suppress some atherogenesis markers, such as cell-ad-
hesion molecules, tumor necrosis factor alfa and super-
oxide (29). A combination of both agents may be more
effective clinically than either one alone and recent trials
show promising results (30, 31).
In view of this, our data indicate that the additive car-
dioprotection obtained with a combined RAS blockade
might be mediated through a concomitant reduction in
collagen. This hypothesis might be supported by recent
results indicating an important role of TGFβ1 and colla-
gen in the occurrence of myocardial fibrosis. In fact, re-
cent experimental studies have shown that improve-
ment of myocardial stiffness may be due to an inhibition
of collagen synthesis rather than to an enhancement of
collagen degradation (32). Collagen synthesis is altered
by load, activation of RAS, neurohumoral and growth
factors. Chronic activation of the RAS increases extra-
cellular matrix and fibrillar collagen, promoting myocar-
dial stiffness and diastolic dysfunction. The use of treat-
ment that blocks RAS might improve diastolic function
through a normalization of fibrillar collagen (16). The An-
giotensin II type receptor is the target of the RAS sys-
tem and its activation promotes ventricular fibrosis and
hypertrophy (33). Experimental data demonstrate that a
combination of ACEi and ARB have additive favorable
effects on ventricular structural abnormalities, diastolic
dysfunction and collagen accumulation (34) that are in-
dependent  of  their  antihypertensive  effectiveness.
These effects might be in part due to the decrease of re-
active oxygen species (ROS) generation. In fact, AII di-
rectly stimulates ROS production promoted by macro-
phage infiltration (35) and the blockade of macrophage
infiltration stops the production of TGFβ1 (36) and ex-
tracellular matrix (37). RAS blockade and cardioprotection
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Finally, combined therapy was characterized by a
good safety profile and it was also supported by main-
tained renal function, left ventricular function and by in-
consistent change in potassium at the end of the treat-
ment. 
However, our study has some possible limitations.
First, it did not have a placebo group; such group was
not approved by the ethics committee because of the
known cardioprotection of ACEi and ARB. This limita-
tion is unlikely to affect our data because both mono-
therapies significantly reduced LVM. Secondly, we have
not assessed the most appropriate dose of each drug in
combination treatment. We do not know if a combina-
tion of reduced doses of both drugs could offer the
same cardioprotection as did the dose we used. In view
of this, Peters et al (38) reported that submaximal doses
of ACEi and ARB, like we used, are able to induce in
combination maximal inhibition of angiotensin II and
provide maximal therapeutic efficacy. In addition another
study showed that addition of an ARB to an ACEi is
more effective than doubling ACEi dose (39). Neverthe-
less dual RAS blockade is a relatively new concept and
some questions remained unanswered. The duration of
action of different ACEi and ARB might influence the ef-
fect of different combinations. Moreover complete RAS
suppression and thus a higher dose or a shorter dose
interval might be needed to obtain organ protection
where lower doses are sufficient to treat hypertension
(40). Finally, it is possible that reduction in LVM/h2.7 af-
ter combined therapy might be underestimated since
not only hypertensive patients recruited by us had left
ventricular hypertrophy.
Some clinical implications arise from the results of
our study. First, combination treatment was well tolerat-
ed without evidence of hyperkaliemia after 24 weeks.
This provided further evidence to suggest that the pre-
sent practice of avoiding use of ACEi and ARB or both,
to prevent renal impairment and hyperkaliemia, is no
longer justified. However, careful observation is still rec-
ommended. In conclusion our data suggest that hyper-
tensive patients with higher LVM may be considered a
particular subset of hypertensives who may particularly
benefit from complete RAS blockade. This indication
might also improve the therapeutic strategy for cardio-
protection in hypertensive subjects.
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